Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Christopher Matheny"'
Autor:
Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 11, Pp 2625-2639 (2022)
Abstract A phase I trial (NCT03447314; 204686) evaluated the safety and efficacy of GSK1795091, a Toll‐like receptor 4 (TLR4) agonist, in combination with immunotherapy (GSK3174998 [anti‐OX40 monoclonal antibody], GSK3359609 [anti‐ICOS monoclon
Externí odkaz:
https://doaj.org/article/49c13d90d7e24ea0911654cd99a602a9
Autor:
Hasan Alsaid, Tinamarie Skedzielewski, Mary V Rambo, Kristen Hunsinger, Bao Hoang, William Fieles, Edward R Long, James Tunstead, Danielle J Vugts, Matthew Cleveland, Neil Clarke, Christopher Matheny, Beat M Jucker
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176075 (2017)
The purpose of this work was to use various molecular imaging techniques to non-invasively assess GSK2849330 (anti HER3 ADCC and CDC enhanced 'AccretaMab' monoclonal antibody) pharmacokinetics and pharmacodynamics in human xenograft tumor-bearing mic
Externí odkaz:
https://doaj.org/article/8a2ccc9895534f1ca10fbfa2c7a01728
Autor:
Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul
Publikováno v:
Scientia
Biological activity; Solid tumors Actividad biológica; Tumores sólidos Activitat biològica; Tumors sòlids A phase I trial (NCT03447314; 204686) evaluated the safety and efficacy of GSK1795091, a Toll-like receptor 4 (TLR4) agonist, in combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d52a2c776e6853dfc712d9d3e7b04e11
https://doi.org/10.1111/cts.13387
https://doi.org/10.1111/cts.13387
Autor:
Gopinath Ganji, Marc Ladanyi, Natasha Rekhtman, Ryma Benayed, Christopher Matheny, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, Victor Martinez, William W. Lockwood, Huichun Tai, Jason Chang, Joseph Montecalvo, Kenneth Ng, Joshua Sabari, Andrew J. Plodkowski, Morana Vojnic, Lukas Delasos, Roger S. Smith, Anja Ruusulehto, Patrice Desmeules, Henrik Edgren, Biju P. Mangatt, Romel Somwar, Alexander Drilon
NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMA) of the lung. The oncoprotein binds ERBB3–ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28aa126b94ea05ed03c9cddacb1ddd07
https://doi.org/10.1158/2159-8290.c.6546853.v1
https://doi.org/10.1158/2159-8290.c.6546853.v1
Autor:
Gopinath Ganji, Marc Ladanyi, Natasha Rekhtman, Ryma Benayed, Christopher Matheny, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, Victor Martinez, William W. Lockwood, Huichun Tai, Jason Chang, Joseph Montecalvo, Kenneth Ng, Joshua Sabari, Andrew J. Plodkowski, Morana Vojnic, Lukas Delasos, Roger S. Smith, Anja Ruusulehto, Patrice Desmeules, Henrik Edgren, Biju P. Mangatt, Romel Somwar, Alexander Drilon
Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310ac60c37faeb853e66623ab0897cde
https://doi.org/10.1158/2159-8290.22532836
https://doi.org/10.1158/2159-8290.22532836
Autor:
Gopinath Ganji, Marc Ladanyi, Natasha Rekhtman, Ryma Benayed, Christopher Matheny, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, Victor Martinez, William W. Lockwood, Huichun Tai, Jason Chang, Joseph Montecalvo, Kenneth Ng, Joshua Sabari, Andrew J. Plodkowski, Morana Vojnic, Lukas Delasos, Roger S. Smith, Anja Ruusulehto, Patrice Desmeules, Henrik Edgren, Biju P. Mangatt, Romel Somwar, Alexander Drilon
Figures S1, S2, S3, S4, and S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3d9c2a4b6110528dde02f9ec88a23da
https://doi.org/10.1158/2159-8290.22532845.v1
https://doi.org/10.1158/2159-8290.22532845.v1
Autor:
Gopinath Ganji, Marc Ladanyi, Natasha Rekhtman, Ryma Benayed, Christopher Matheny, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, Victor Martinez, William W. Lockwood, Huichun Tai, Jason Chang, Joseph Montecalvo, Kenneth Ng, Joshua Sabari, Andrew J. Plodkowski, Morana Vojnic, Lukas Delasos, Roger S. Smith, Anja Ruusulehto, Patrice Desmeules, Henrik Edgren, Biju P. Mangatt, Romel Somwar, Alexander Drilon
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30adbe9b1b076dd2ef4249bcf72b055f
https://doi.org/10.1158/2159-8290.22532842
https://doi.org/10.1158/2159-8290.22532842
Autor:
Alexander Drilon, Martijn P. Lolkema, Hui K Gan, Robert C. Gagnon, Gopinath Ganji, Carla L.M. Van Herpen, Ignacio Garrido-Laguna, Bruce A. Hug, Jason D. Lickliter, Robin O'Connor-Semmes, Jan H.M. Schellens, Catherine E. Ellis, Christopher Matheny, Michael Millward, Mathilde Jalving, Lihua Tang
Publikováno v:
The Oncologist, 26(10), e1844-e1853. ALPHAMED PRESS
The Oncologist
Oncologist, 26, 10, pp. e1844-e1853
Oncologist, 26, e1844-e1853
The Oncologist
Oncologist, 26, 10, pp. e1844-e1853
Oncologist, 26, e1844-e1853
Background GSK2849330, an anti‐HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signaling in cancer cells, is engineered for enhanced antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity. This phase I, fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca765b079fda30d6838b7dbd1c38708d
https://hdl.handle.net/2066/244559
https://hdl.handle.net/2066/244559
Autor:
E Antonio Chiocca, Hiroshi Nakashima, Xiaokui Mo, Isaac Solomon, Alexander Ling, Jared Woods, Joshua Bernstock, Genaro Villa, Raziye Piranlioglu, Ana Montalvo Landivar, Nafisa Masud, Daniel Triggs, James Grant, Patrick Y Wen, Eudocia Lee, Lakshmi Nayak, Ugonma Chukwueke, Tracy Batchelor, David Krisky, Estuardo Aguilar-Cordova, Laura K Aguilar, Soledad Fernandez, Christopher Matheny, Andrea Manzanera, Francesca Barone, Paul Peter Tak, Keith Ligon, David A Reardon
Publikováno v:
Neuro-Oncology. 24:vii61-vii61
BACKGROUND CAN-3110 (rQNestin34.5v2) is an HSV-1 oncolytic viral immunotherapy with one copy of the inflammatory ICP34.5 gene under transcriptional control of the Nestin glioma-specific promoter. We completed a phase 1 sequential dose-escalation tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19461b0ab541fea08c319be4c93a0c22
https://doi.org/10.1093/neuonc/noac209.241
https://doi.org/10.1093/neuonc/noac209.241
Autor:
Anja Ruusulehto, Andrew J. Plodkowski, Victor D. Martinez, Roger S. Smith, Jason C. Chang, Marc Ladanyi, Maria E. Arcila, Henrik Edgren, Kenneth K.-S. Ng, Gopinath Ganji, Charles M. Rudin, Christopher Matheny, Joshua K. Sabari, Joseph Montecalvo, Huichun Tai, Romel Somwar, Lukas Delasos, Natasha Rekhtman, Alexander Drilon, Ryma Benayed, Gregory J. Riely, Biju Mangatt, Mark G. Kris, Morana Vojnic, William W. Lockwood, Patrice Desmeules
Publikováno v:
Cancer Discovery. 8:686-695
NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMA) of the lung. The oncoprotein binds ERBB3–ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba87b5e5e83002dac2bfef7860f03a85
https://doi.org/10.1158/2159-8290.cd-17-1004
https://doi.org/10.1158/2159-8290.cd-17-1004